Cystatin C levels and risk of death from all causes

Slides:

Advertisements

Similar presentations

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.

Advertisements

Cholesterol quintile (mg/dL)

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.

Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Slide Source: Lipids Online Slide Library LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

NSTE Acute Coronary Syndromes

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC Time (days)

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Predictive value of CRP vs LDL-C (i) Ridker PM, et al. N Engl J Med 2002;347: Quintile of CRP (mg/L)

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

(p for noninferiority = 0.01)

Structure of Cis and Trans Fatty Acids

IRIS Trial design: Patients without diabetes with a history of stroke or TIA within 6 months, with objective evidence of insulin resistance (HOMA-IR value.

LEADER trial: Primary Outcome

Baseline Demographic and Clinic Variables According to Office vs 24-Hour or Home BP Giuseppe Mancia, et al. Hypertension 2006;47;

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Fig 3. Time trends for infant mortality rate and hazard ratio according to the deprivation quintiles. (A) Time trend for the infant mortality rate according.

TNT: Baseline and final LDL cholesterol levels

CHOICE: Relative risk of death on peritoneal dialysis vs hemodialysis

Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic

Summary of Design Aim: Effect of Ramipril (up to 10mg/d) or Vit E (400 IU/d) vs its placebo on CV death, M I or stroke (primary) Design: Randomized double.

Adjusted mortality risk

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

LIFE: Reduction in primary end-point events seen with reduction of LVH by two electrocardiographic criteria End point % reduction with each 1050-mm x ms.

PREMIER: Rate of hypertension at 18 months

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

Rounded incidence values (%) of renal and nonrenal events

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

Association between highest tertile for homocysteine and mortality

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

ASCOT-BPLA: Primary and secondary end points

Relative risk of major events with atenolol vs placebo

Outcome Relative risk with beta blockers 95% CI Stroke –1.30

Health ABC: Mortality risk by quintile of cystatin C

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

Adjusted odds ratio for hypoglycemia with gatifloxacin and levofloxacin compared with macrolide antibiotics Antibiotic Odds ratio of hypoglycemia 95% CI.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Measure Acute rejection Chronic allograft nephropathy

(p for noninferiority < 0.001)

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

The ONgoing Telmisartan Alone and in

Patient characteristics: American vs Canadian transplant patients

Baseline Characteristics of the Subjects

Risk of mortality and fatal and nonfatal cardiovascular events in highest vs lowest quartiles for troponin T End point Relative risk 95% CI p Mortality.

Characteristics of Study Subjects and Events, According to the Quintile of Exposure to Fine Particulate Matter (PM2.5)* - Part I Kristin A. Miller et al.

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

A Single Participant Exposed Twice to an Inflammatory Stimulus

Cardiovascular risk in chronic kidney disease

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

End Points: ONTARGET vs. HOPE *

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

Outcomes Group Number of events Total person-years aIRR (95%CI)

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Presentation transcript:

Cystatin C levels and risk of death from all causes Cystatin C level (mg/L) Hazard ratio (adjusted) (95% CI) Quintile 1 (<0.89) 1.00 Quintile 2 (0.90-0.99) 1.08 (0.86-1.35) Quintile 3 (1.00-1.10) 1.23 (1.00-1.53) Quintile 4 (1.11-1.28) 1.34 (1.09-1.66) Quintile 5a (1.29-1.39) 1.77 (1.34-2.26) Quintile 5b (1.40-1.59) 2.18 (1.72-2.78) Quintile 5c (>1.60) 2.58 (2.03-3.27) Shlipak MG et al. N Engl J Med 2005; 352:2049-2060.

Creatinine levels and risk of death from all causes Creatinine level (values in men/women [mg/L]) Hazard ratio (adjusted) (95% CI) Quintile 1 (<0.85/0.65) 1.00 Quintile 2 (0.86-1.05/0.66-0.75) 0.70 (0.57-0.85) Quintile 3 (1.06-1.15/0.76-0.85) 0.84 (0.68-1.04) Quintile 4 (1.16-1.25/0.86-0.95) 0.83 (0.66-1.03) Quintile 5a (1.26-1.35/0.96-1.05) 1.00 (0.79-1.27) Quintile 5b (1.36-1.55/1.06-1.15) 0.95 (0.74-1.22) Quintile 5c (>1.56/1.16) 1.48 (1.18-1.85) Shlipak MG et al. N Engl J Med 2005; 352:2049-2060.

Adjusted risk for CV death, MI, and stroke in highest (>1 Adjusted risk for CV death, MI, and stroke in highest (>1.29 mg/L) vs two lowest (< 0.99 mg/L) quintiles of cystatin C End point Hazard ratio (95% CI) CV death 2.27 (1.73-2.97) MI 1.48 (1.08-2.02) Stroke 1.47 (1.09-1.96) Shlipak MG et al. N Engl J Med 2005; 352:2049-2060.